Dtil is a good buy?

Precision BioSciences (DTIL) appears to be a good buy based on the following points:

1. Strong Fundamentals: Precision BioSciences has a robust gene editing platform and has made significant progress in developing in vivo gene editing therapies. The company's focus on sophisticated gene edits and its ability to generate Phase 1 clinical data across multiple programs are positive indicators.
2. Financial Strength: The company has a strong balance sheet, as evidenced by the maturity of a $13 million convertible note from Imugene Limited, which includes cash and Imugene ordinary shares. This provides the company with additional financial resources to advance its pipeline.
3. Positive Analyst Sentiment: Wall Street analysts have set a high mean price target of $39.61, indicating a potential upside of 307.9% from the current price. This suggests that analysts believe the stock has significant growth potential.
4. Recent Developments: Precision BioSciences has announced a strategic transaction with Imugene that bolsters its balance sheet and advances its in vivo gene editing programs. This strategic move is likely to contribute to the company's future growth.
5. Investor Confidence: There has been a recent increase in investor confidence, as evidenced by the purchase of a new stake in Precision BioSciences by Janus Henderson Group PLC. This is a positive sign, as it suggests that other investors see potential in the company.

In conclusion, Precision BioSciences (DTIL) seems to be a good buy based on its strong fundamentals, financial strength, positive analyst sentiment, recent developments, and increased investor confidence. However, it's important to conduct your own research and consider your investment goals and risk tolerance before making any investment decisions.